mercredi 22 février 2017

Onco Actu du 22 février 2017

4. Dépistage, diagnostic et pronostic

Can Craig Venter Cheat Death? [Forbes]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

Is the United States Preventive Services Task Force still a voice of caution? [BMJ]

4.10 Dép., diag. & prono. - Poumon

We Can Find Lung Cancer Early And Save Lives, So Why Aren’t More Smokers And Former Smokers Getting Screened? [Dr. Len]

4.5 Dép., diag. & prono. - Colorectal

One-off bowel scope cuts cancer risk for at least 17 years [Cancer Research UK]

New screening test cuts bowel cancer risk by a third, study finds [The Guardian]

4.9 Dép., diag. & prono. - Sein

Screening MRI Benefits Women at Average Risk of Breast Cancer [RSNA]

5.10 Traitements - Essais

TAPUR Trial Expands Who Can Join Clinical Trials, If Payers Fund Genomic Tests [AJMC]

Phase II Study Supports Potential for Atezolizumab plus Bevacizumab for Locally Advanced or Metastatic Renal Cell Carcinoma [ESMO]

5.12 Immunothérapies

FDA’s Pazdur and Blumenthal: The March of Checkpoint Inhibitors Will Continue [RAPS]

5.12.5 Immunothérapies - Pharma

Lead cancer immunotherapy candidate receives FDA fast track designation [Cell Medica]

5.2 Pharma

FDA accepts Pfizer’s blood cancer candidate for speedy review [FierceBiotech]

VBL posts additional data from phase 2 thyroid cancer trial [FierceBiotech]

Pfizer Announces Acceptance of Regulatory Submission for Inotuzumab Ozogamicin by the U.S. Food and Drug Administration [Pfizer]

Pfizer shortens comeback campaign for armed antibody inotuzumab, lands quick FDA review [EndPoints]

5.2.2 Pharma - Fusions & Acquisitions

Buyout buzz swells for the giant Bristol-Myers after Carl Icahn makes an entrance, stage left [EndPoints]

5.2.3 Pharma - économie

AstraZeneca's latest Kondo-izing move: A $250M-plus deal for cancer med Zoladex [FiercePharma]

5.4 Traitements - Economie

NICE draft guidelines reject Ipsen’s Cabometyx [PharmaTimes]

5.5.4 ASCO (immunothérapies)

Utility of Biomarkers for Predicting Colorectal Cancer Survival Depends on Tumor Location [ASCO]

Response to Cancer Immunotherapy May Depend on Gut Bacteria [ASCO]

6.1 Observation

Annals of Oncology Press Release: Death Rates from Cancer will Fall Faster in Men than in Women in Europe in 2017 [ESMO]

U.S. Cancer Mortality Rates Falling, But Some Regions Left Behind, Study Finds [NCI]

Life expectancy study shows many likely to live beyond 90 by 2030 [Reuters]

6.10 Politiques

China biotech makes big data a weapon in its war on cancer [China Daily]

6.11 Patients

The real quest of cancer treatment: dispensing the right mix of hope and reality [The Guardian]

Steve Hewlett’s legacy could be to save lives by raising cancer awareness [The Guardian]

6.6 Publications

No publication without confirmation [Nature]

Got “significosis?” Here are the five diseases of academic publishing [Retraction Watch]

6.7 DMP, Big Data & applis

Computer algorithm predicts outcome for leukemia patients [Stanford Medicine]